Taigen Biopharmaceutica (Taiwan) Performance
| 4157 Stock | TWD 11.45 0.35 2.97% |
The entity has a beta of -0.25, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Taigen Biopharmaceutica are expected to decrease at a much lower rate. During the bear market, Taigen Biopharmaceutica is likely to outperform the market. At this point, Taigen Biopharmaceutica has a negative expected return of -0.35%. Please make sure to validate Taigen Biopharmaceutica's mean deviation, standard deviation, total risk alpha, as well as the relationship between the coefficient of variation and jensen alpha , to decide if Taigen Biopharmaceutica performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Taigen Biopharmaceuticals Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in January 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors. ...more
| Begin Period Cash Flow | 60.9 M | |
| Total Cashflows From Investing Activities | -306.1 M |
Taigen |
Taigen Biopharmaceutica Relative Risk vs. Return Landscape
If you would invest 1,440 in Taigen Biopharmaceuticals Holdings on September 16, 2024 and sell it today you would lose (295.00) from holding Taigen Biopharmaceuticals Holdings or give up 20.49% of portfolio value over 90 days. Taigen Biopharmaceuticals Holdings is generating negative expected returns and assumes 1.5277% volatility on return distribution over the 90 days horizon. Simply put, 13% of stocks are less volatile than Taigen, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Taigen Biopharmaceutica Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Taigen Biopharmaceutica's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Taigen Biopharmaceuticals Holdings, and traders can use it to determine the average amount a Taigen Biopharmaceutica's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2264
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 4157 |
Estimated Market Risk
| 1.53 actual daily | 13 87% of assets are more volatile |
Expected Return
| -0.35 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.23 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Taigen Biopharmaceutica is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Taigen Biopharmaceutica by adding Taigen Biopharmaceutica to a well-diversified portfolio.
Taigen Biopharmaceutica Fundamentals Growth
Taigen Stock prices reflect investors' perceptions of the future prospects and financial health of Taigen Biopharmaceutica, and Taigen Biopharmaceutica fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Taigen Stock performance.
| Return On Equity | -0.21 | |||
| Return On Asset | -0.15 | |||
| Operating Margin | (9.40) % | |||
| Current Valuation | 11.41 B | |||
| Shares Outstanding | 716.84 M | |||
| Price To Book | 11.51 X | |||
| Price To Sales | 369.99 X | |||
| Revenue | 1.29 B | |||
| EBITDA | 905.1 M | |||
| Book Value Per Share | 1.50 X | |||
| Cash Flow From Operations | 629.07 M | |||
| Earnings Per Share | 1.08 X | |||
| Total Asset | 1.39 B | |||
About Taigen Biopharmaceutica Performance
Evaluating Taigen Biopharmaceutica's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Taigen Biopharmaceutica has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Taigen Biopharmaceutica has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Things to note about Taigen Biopharmaceutica performance evaluation
Checking the ongoing alerts about Taigen Biopharmaceutica for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Taigen Biopharmaceutica help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Taigen Biopharmaceutica generated a negative expected return over the last 90 days | |
| Taigen Biopharmaceutica has high likelihood to experience some financial distress in the next 2 years | |
| About 36.0% of the company shares are owned by insiders or employees |
- Analyzing Taigen Biopharmaceutica's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Taigen Biopharmaceutica's stock is overvalued or undervalued compared to its peers.
- Examining Taigen Biopharmaceutica's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Taigen Biopharmaceutica's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Taigen Biopharmaceutica's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Taigen Biopharmaceutica's stock. These opinions can provide insight into Taigen Biopharmaceutica's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Taigen Stock Analysis
When running Taigen Biopharmaceutica's price analysis, check to measure Taigen Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Taigen Biopharmaceutica is operating at the current time. Most of Taigen Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of Taigen Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Taigen Biopharmaceutica's price. Additionally, you may evaluate how the addition of Taigen Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.